Maintenance Notice (3:15 - 7:30 AM February 22, 2025 UTC): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Notice of Discontinuing the Use of Password-Protected Compressed Files | Product Document Searching Made Easy by 2D Code! | TCI Life Science News February 2025 | [Product Highlights] Chemiluminescent Reagents for... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 192927-63-2 | Product Number: M2479
Moxifloxacin Hydrochloride Monohydrate
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-1H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic Acid Hydrochloride Monohydrate
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 100MG |
$113.00
|
4 | 1 | Contact Us | |
| 1G |
$567.00
|
15 | 3 | Contact Us |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | M2479 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__1H__2__4FN__3O__4·HCl·H__2O = 455.92 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Packaging and Container | 100MG-Glass Bottle with Plastic Insert (View image), 1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 192927-63-2 |
| Related CAS RN | 186826-86-8&151096-09-2 |
| Reaxys Registry Number | 8377447 |
| PubChem Substance ID | 354334556 |
| Merck Index (14) | 6291 |
| MDL Number | MFCD00949117 |
Specifications
| Appearance | White to Orange to Green powder to crystaline |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Specific rotation [a]20/D | -124 to -137 deg(C=0.5, water) |
| Water | 3.0 to 5.0 % |
Properties (reference)
| Melting Point | 240 °C(dec.) |
| Maximum Absorption Wavelength | 338 nm (H__2O) |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H341 : Suspected of causing genetic defects. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P405 : Store locked up. |
Related Laws:
| RTECS# | VB1983750 |
Transport Information:
| H.S.code* | 2933.49-000 |
Application
Moxifloxacin Hydrochloride: A Fluoroquinolone Antibacterial with a Methoxy Group in the C-8 Position
Moxifloxacin hydrochloride (BAY 12-8039) is a synthetic fluoroquinolone antibacterial agent with in vitro activity against a wide range of Gram-positive and Gram-negative bacteria. The bactericidal action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) in Gram-negative bacteria and topoisomerase IV in Gram-positive bacteria required for bacterial DNA replication, transcription, repair, and recombination. It is reported that the C8-methoxy moiety contributes to enhanced activity and lower selection of resistant mutants of Gram-positive bacteria compared to the C8-H moiety. Therefore, moxifloxacin has improved activity against Gram-positive species (including staphylococci, streptococci, enterococci) compared with ciprofloxacin [ C2510, C2227 (HCl salt)]. Recently, antituberculosis activity of moxifloxacin has been reported. (The product is for research purpose only.)
References
- 1)In vitro Activity of BAY 12-8039, a New 8-Methoxyquinolone
- 2)The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus
- 3)In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis
- 4)Moxifloxacin: A review of its use in the management of bacterial infections
- 5)Simultaneous determination of levofloxacin, gatifloxacin and moxifloxacin in serum by liquid chromatography with column switching
- 6)Optimization of separation and determination of moxifloxacin and its related substances by RP-HPLC
- 7)Solubility of Antibiotics in Different Solvents. 1. Hydrochloride Forms of Tetracycline, Moxifloxacin, and Ciprofloxacin
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.